Saturday 17 October 2026
Export GILD’s income statement to Excel — free account
Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
156.19
1.18
−0.75%
Follow GILD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
17.92 | 243.08 | 18.29 | 23.27 | 14.67 | 582.60 | 15.33 | 14.89 | 20.93 | 7.36 |
Piotroski F-Score |
8 | 7 | 7 | 8 | 7 | 6 | 8 | 7 | 5 | 5 |
P/S ratio |
5.19 | 4.01 | 3.83 | 3.93 | 3.34 | 2.97 | 3.68 | 3.67 | 3.71 | 3.27 |
Altman Z-Score |
4.03 | 2.74 | 2.84 | 2.76 | 2.44 | 1.81 | 2.70 | 2.82 | 2.89 | 3.75 |
Altman Z″-Score (non-manufacturers) |
3.28 | 2.13 | 2.79 | 2.45 | 2.54 | 1.91 | 4.29 | 4.98 | 4.55 | 4.85 |
P/FCF ratio |
16.15 | 11.18 | 14.00 | 12.84 | 8.44 | 9.74 | 9.92 | 10.86 | 8.56 | 6.09 |
Beneish M-Score |
(2.45) | (3.42) | (2.72) | (2.80) | (2.83) | (2.55) | (2.62) | (2.89) | (3.19) | (2.88) |
P/Operating CF |
45.89 | 38.72 | 47.89 | 41.75 | 28.46 | 38.22 | 31.99 | 34.62 | 35.18 | 28.06 |
Dividend Safety Score |
77 | — | — | — | — | — | — | — | — | — |
P/B ratio |
6.75 | 5.98 | 4.57 | 5.05 | 4.33 | 4.02 | 3.64 | 3.77 | 4.72 | 5.13 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.38 | 48.36 | 0.00 | 10.77 |
EV/Sales |
5.77 | 4.59 | 4.53 | 4.66 | 4.11 | 3.99 | 3.73 | 3.59 | 4.04 | 3.78 |
EV/EBITDA |
13.30 | 29.78 | 11.93 | 13.48 | 9.39 | 17.73 | 14.72 | 8.25 | 6.84 | 6.11 |
EV/Operating CF |
16.97 | 12.18 | 15.35 | 14.02 | 9.87 | 12.05 | 9.16 | 9.46 | 8.86 | 6.73 |
EV/FCF |
17.98 | 12.80 | 16.56 | 15.24 | 10.40 | 13.09 | 10.07 | 10.63 | 9.32 | 7.04 |
Quick Ratio |
1.06 | 1.20 | 1.06 | 0.99 | 0.95 | 1.08 | 2.86 | 3.15 | 2.52 | 1.78 |
Current Ratio |
1.55 | 1.60 | 1.43 | 1.29 | 1.27 | 1.40 | 3.10 | 3.38 | 2.74 | 2.13 |
Net Debt/EBITDA |
1.35 | 3.78 | 1.85 | 2.12 | 1.77 | 4.54 | 0.22 | (0.18) | 0.56 | 0.78 |
Debt/Assets |
42.25% | 45.28% | 42.28% | 41.81% | 40.72% | 47.68% | 41.54% | 44.54% | 48.52% | 46.76% |
Debt/Equity |
1.10 | 1.39 | 1.15 | 1.25 | 1.31 | 1.79 | 1.13 | 1.32 | 1.66 | 1.38 |
Asset Turnover |
0.50 | 0.47 | 0.43 | 0.42 | 0.40 | 0.38 | 0.36 | 0.33 | 0.41 | 0.56 |
Operating CF/Net income |
1.18 | 22.56 | 1.41 | 1.98 | 1.83 | 66.41 | 1.70 | 1.54 | 2.57 | 1.26 |
Capex/Depreciation |
(0.20) | (0.19) | (0.22) | (0.35) | (0.28) | (0.44) | (0.59) | (0.65) | (0.46) | (0.65) |
Interest Coverage |
9.79 | 1.70 | 8.06 | 7.84 | 9.91 | 4.14 | 4.31 | 7.61 | 12.63 | 18.29 |
| 40.66% | 2.29% | 25.77% | 21.73% | 31.69% | 0.60% | 24.38% | 25.95% | 23.22% | 70.18% | |
| 14.42% | 0.79% | 9.04% | 7.00% | 9.13% | 0.19% | 8.60% | 8.14% | 7.27% | 24.84% | |
ROIC |
15.69% | 2.89% | 11.38% | 11.11% | 14.68% | 5.86% | 11.21% | 25.87% | 30.34% | 32.31% |
Return on Tangible Assets |
70.13% | 3.81% | 55.97% | 52.90% | 75.15% | 1.29% | 21.51% | 18.66% | 19.71% | 102.01% |
Average Days of Receivables |
60.91 | 56.11 | 62.73 | 63.91 | 60.06 | 72.32 | 58.24 | 54.88 | 53.84 | 54.22 |
Research and Development Expense of Revenue |
19.70% | 20.54% | 21.09% | 18.24% | 16.85% | 19.96% | 18.06% | 17.72% | 14.30% | 16.78% |
Selling, General and Administrative Expense of Revenue |
19.61% | 21.18% | 22.46% | 20.79% | 19.21% | 20.86% | 19.52% | 18.33% | 14.85% | 11.18% |
Intangible Assets out of Total Assets |
0.43 | 0.48 | 0.56 | 0.59 | 0.61 | 0.60 | 0.29 | 0.31 | 0.30 | 0.18 |
Share Based Compensation of Revenue |
3.04% | 2.90% | 2.82% | 2.33% | 2.33% | 2.60% | 2.83% | 3.82% | 2.44% | 1.25% |
Graham Net Nets |
(0.12) | (0.18) | (0.22) | (0.26) | (0.35) | (0.47) | (0.11) | (0.08) | (0.19) | (0.18) |
Graham Number |
52.94 | 11.49 | 43.20 | 37.36 | 43.22 | 5.71 | 41.25 | 39.60 | 35.35 | 57.27 |
Earnings Yield |
5.58% | 0.41% | 5.47% | 4.30% | 6.82% | 0.17% | 6.53% | 6.71% | 4.78% | 13.59% |
Free Cash Flow Yield |
6.19% | 8.95% | 7.14% | 7.79% | 11.85% | 10.27% | 10.08% | 9.21% | 11.68% | 16.41% |
Revenue per Share |
23.67 | 23.06 | 21.73 | 21.74 | 21.74 | 19.64 | 17.68 | 17.05 | 19.97 | 22.70 |
Operating CF per Share |
8.05 | 8.68 | 6.42 | 7.23 | 9.06 | 6.50 | 7.20 | 6.47 | 9.10 | 12.73 |
Capex per Share |
(0.45) | (0.42) | (0.47) | (0.58) | (0.46) | (0.52) | (0.65) | (0.71) | (0.45) | (0.56) |
Free Cash Flow per Share |
7.60 | 8.26 | 5.95 | 6.65 | 8.60 | 5.98 | 6.55 | 5.76 | 8.65 | 12.17 |
Cash per Share |
6.14 | 8.01 | 5.82 | 5.09 | 5.19 | 5.89 | 19.17 | 23.18 | 19.52 | 8.88 |
Shareholders Equity per Share |
18.18 | 15.43 | 18.23 | 16.90 | 16.77 | 14.50 | 17.83 | 16.59 | 15.69 | 14.46 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
18.18 | 15.43 | 18.23 | 16.90 | 16.77 | 14.50 | 17.83 | 16.59 | 15.69 | 14.46 |
Free Cash Flow |
9,456.00 | 10,305.00 | 7,421.00 | 8,344.00 | 10,805.00 | 7,518.00 | 8,319.00 | 7,476.00 | 11,308.00 | 16,299.00 |
Working Capital |
6,529.00 | 7,169.00 | 4,805.00 | 3,206.00 | 3,162.00 | 4,599.00 | 20,537.00 | 25,231.00 | 20,188.00 | 10,370.00 |
Capital Expenditures |
(563.00) | (523.00) | (585.00) | (728.00) | (579.00) | (650.00) | (825.00) | (924.00) | (590.00) | (748.00) |
Net Current Asset Value |
(18,063.00) | (20,576.00) | (23,291.00) | (27,519.00) | (32,116.00) | (34,190.00) | (8,681.00) | (6,305.00) | (17,959.00) | (18,026.00) |
EV/EBIT |
16.96 | 79.37 | 16.16 | 17.35 | 11.33 | 24.18 | 19.54 | 9.69 | 7.47 | 6.51 |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 |
Price to Operating Income |
15.24 | 69.31 | 13.66 | 14.62 | 9.20 | 17.99 | 19.25 | 9.90 | 6.86 | 5.63 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.49 | 0.51 | 0.51 | 0.38 | 0.40 | 0.30 | 0.31 | 0.36 | 0.39 | 0.40 |
Cash ROIC |
17.13% | 18.42% | 13.19% | 15.45% | 19.55% | 12.91% | 11.46% | 9.35% | 14.12% | 28.15% |
Accounts Receivable Turnover |
6.31 | 6.33 | 5.75 | 5.89 | 5.82 | 5.83 | 6.50 | 6.17 | 6.24 | 5.86 |
Accounts Payable Turnover |
8.05 | 9.04 | 8.93 | 7.03 | 8.52 | 5.87 | 6.22 | 6.05 | 4.33 | 3.57 |
Inventory Turnover |
3.58 | 3.58 | 3.95 | 3.62 | 4.00 | 3.51 | 5.39 | 6.01 | 3.66 | 2.41 |
Average Days of Payables |
41.86 | 48.64 | 30.89 | 58.39 | 38.98 | 67.38 | 55.67 | 59.42 | 67.97 | 103.31 |
Days of Inventory on Hand |
103.87 | 99.85 | 100.38 | 97.23 | 89.47 | 134.36 | 71.99 | 61.22 | 66.89 | 135.94 |
Average Receivables |
4,666.50 | 4,540.00 | 4,718.50 | 4,635.00 | 4,692.50 | 4,237.00 | 3,454.50 | 3,589.00 | 4,182.50 | 5,184.00 |
Average Payables |
774.00 | 691.50 | 727.50 | 805.00 | 774.50 | 778.50 | 751.50 | 802.00 | 1,010.00 | 1,192.00 |
Average Inventory |
1,742.00 | 1,748.50 | 1,647.00 | 1,562.50 | 1,650.50 | 1,302.50 | 868.00 | 807.50 | 1,194.00 | 1,771.00 |
Average Assets |
59,009.00 | 60,560.00 | 62,648.00 | 65,561.50 | 68,179.50 | 65,017.00 | 62,651.00 | 66,979.00 | 63,630.00 | 54,346.50 |
Average Common Equity |
20,932.00 | 20,997.50 | 21,979.00 | 21,136.50 | 19,642.50 | 20,435.50 | 22,092.00 | 21,017.50 | 19,932.00 | 19,238.00 |
Columns are period end dates